On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S. Food and Drug Administration for their mRNA-based combination vaccine candidate for influenza and COVID-19, which aims to help prevent two respiratory diseases with a single injection.